SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its genomic and molecular testing capabilities [1][8] - The partnership with the Hematology Translational Lab at the University of Calgary has significantly advanced precision oncology and immunology research [1] - Liquid biopsy testing, which extracts cell-free DNA from blood plasma, offers a less invasive alternative to traditional biopsies, facilitating quicker clinical decisions and monitoring [2][9] Company Developments - OncoHelix will utilize the new liquid biopsy solution to enhance its oncology testing capabilities, building on its existing use of the SOPHiA DDM™ Platform for myeloid testing [8][9] - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, focusing on deep sequencing of 146 cancer-associated genes [9] - The implementation of this technology is expected to improve the assessment of cancer treatment responses and the diagnosis of cases where tissue biopsy is not feasible [3][9] Industry Context - SOPHiA GENETICS is a leader in data-driven medicine, utilizing AI to provide actionable insights for healthcare institutions globally [5] - The collaboration between OncoHelix and SOPHiA GENETICS reflects a growing trend in the healthcare industry towards integrating advanced genomic technologies to improve patient care [9]